Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: DESTINY-PanTumor02 demonstrated clinically meaningful activity of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gynecologic cancers, contributing to regulatory approval for unresectable or metastatic HER2 immunohistochemistry (IHC) 3+ solid tumors. Evidence in gynecologic malignancies with low HER2 expression remains limited. We evaluated T-DXd in a predominantly HER2-low, heavily pretreated population. Methods: This retrospective, single-center cohort study included 11 patients with recurrent gynecologic malignancies who initiated therapy with T-DXd at the Medical University of Innsbruck between January 2024 and February 2026 following progression on standard-of-care treatment. The cohort comprised patients with ovarian (n = 6), endometrial (n = 2), and cervical cancer (n = 3). Treatment response, survival outcomes, and adverse events were assessed. Results: Among 11 heavily pretreated patients, seven (64%) had tumors with HER2 IHC 1+, three (27%) had HER2 IHC 2+/ISH negative, and one (9%) had HER2 IHC 3+ expression. The overall response rate was 67% (6/9; 95% CI 29.9–92.5) and disease control rate was 78% (7/9; 95% CI 40.0–97.2). Kaplan–Meier median duration of response was 4.6 months (95% CI, 1.9–7.3), with two responses ongoing at 8.7 and 20.1 months. Median progression-free and overall survival were 7.0 months (95% CI, 1.6–12.4) and 12.0 months (95% CI, 8.3–15.7), respectively. Treatment-associated adverse events occurred in 73% of patients, including interstitial lung disease in two patients. Conclusions: T-DXd showed antitumor activity in this predominantly HER2-low real-world cohort. These findings support further clinical investigation of T-DXd in patients with low HER2 expressing gynecological malignancies.
Source: Cancers
Authors: Katharina Leitner(Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review & editing), Irina Tsibulak(Conceptualization, Data curation, Writing – review & editing), Christoph Ebner(Conceptualization, Data curation, Writing – review & editing), Barin Feroz(Conceptualization, Data curation, Writing – review & editing), Katharina Steger(Conceptualization, Data curation, Writing – review & editing), Susanne Sprung(Data curation, Writing – review & editing), Christian Marth(Conceptualization, Data curation, Writing – review & editing), Ibrahim Alkatout(Conceptualization, Data curation, Writing – review & editing), Verena Wieser(Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing)
Institutions: Innsbruck Medical University, Tirol Kliniken
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7235656529
